The effect of a cloned allospecific human Th cell, termed 86 
Introduction
The development of effective, antigen specific, adoptive immunotherapy for tumors and intracellular infections represents a major objective of cellular immunology. In a number of experimental systems, considerable progress has been made toward achieving this goal. For example, virus or tumor antigen specific, murine cytolytic T lymphocytes (CTL),' induced and/or expanded in vitro in the presence of antigen presenting cells and IL-2, have been shown to effectively augment cellmediated immunity upon in vivo transfer into virally infected or tumor-bearing syngeneic mice (1) (2) (3) (4) . In more recent studies by Cheever et al. (5) , Friend virus leukemia specific CTL, grown in vitro in the presence ofantigen presenting cells alone, were adoptively transferred and shown to both mediate 1. Abbreviations used in this paper: AFC, antibody-forming cells; CTL, cytolytic T lymphocytes; LAK, lymphokine-activated killer cells; NK, natural killer cells; Th, T (6) . While appealing, the direct application of this technique to human disease is complicated by the difficulty in generating Th cells specific for weak (i.e., tumor) antigens, the problems associated with MHC disparities between the Th cell donor and the tumor-bearing recipient, and the possibility of tumor antigen-specific suppressor T cells that can impede an effective immune response (7) .
A potential strategy to circumvent these obstacles was suggested by our observation of functional heterogeneity among cloned human Th cell lines (8) . We described two types of CD4+, CD8-allospecific T cell clones that mediate reciprocating helper functions: one preferentially triggers the differentiation of B cells into antibody forming cells (AFC), while the other selectively amplifies allospecific CTL responses. We postulated that these two functionally distinct Th subsets may differ with respect to the spectrum of lymphokines that they elaborate. More recently, evidence for a similar division of labor among Th cells has emerged in both the rat (9) and murine models (10) .
The studies described in this report were designed to determine if cloned alloreactive human Tb cells can be utilized to enhance CTL responses against more physiologically relevant targets, namely altered self cells. To this end, we have focused on the in vitro generation of human CTL that lyse hapten modified autologous lymphocytes. This model was chosen as the cellular interactions required for CTL generation ( 11) and effector cell specificity (12, 13) of hapten altered self-reactive CTL appear to be analogous to those for autologous tumor and virally infected cells (14) (15) (16) (17) . Our results demonstrate that selected allospecific Th cells can function to markedly amplify the in vitro generation of hapten-altered self-specific, CD4-, CD8+ human CTL. These effector cells grow well in vitro and mediate extremely efficient cytolytic activity. While these allospecific Th cells function at least in part by the secretion of lymphokines, the capacity of Th cells to bind (18, 19) and present (19) antigen to the immune system suggests that these cells may permit a novel immunotherapeutic strategy for human diseases. lated from non-T cells by E rosette formation with neuraminidasetreated sheep red blood cells and a second Ficoll-Hypaque centrifugation, as previously described (20) . In some experiments, T Hapten altered self-reactive CTL induction and effector assays. The in vitro generation and functional assay of hapten altered self-reactive human CTL have been described in detail (20, 22 As shown in Fig. 3 , CTLs generated under these culture conditions lyse TNP modified, but not unmodified, autologous targets and cytolysis is markedly inhibited by preincubating target cells with a monoclonal antibody directed against either a framework determinant on MHC class I molecules (W6/32) or an anti-beta-2 microglobulin specific antibody (NAMB-1). In contrast, antibodies to MHC class II framework determinants (L243) or a polymorphic MHC class I determinant of the HLA-A-2 molecule (CR1 1-351) or the A3 molecule (GAPA3), are without significant effect.
The inability of GAPA3, which binds to the HLA A-3 molecule expressed on the target cell, to block cytolysis ( Fig. 3) suggests that the altered self-reactive CTL induced in this study are directed against other target cell specificities. In this regard, while in all studies the CTL generated preferentially lyse TNP modified autologous targets, these effector cells do lyse, to a significant extent, TNP modified allogeneic targets, which share no serologically defined MHC class I antigens with the CTL donor (Table I ). This result is consistent with a previous report demonstrating that a large proportion (40-80%) ofTNP specific human CTL are restricted by nonpolymorphic, species specific determinants, presumably expressed on HLA class I molecules (13) .
The study depicted in Fig. 4 We would emphasize, however, that the addition of larger numbers of Th cells, while not increasing the level of cytotoxicity generated at any effector to target ratio, increased by two-to threefold the number of viable effector T cells generated at the end of 6 d of culture. Therefore, although relatively small numbers of Th cells can induce significant CTL activity, larger numbers amplify the proliferative response of the responder T cells thereby generate more CTLs during the period of culture.
The capacity of cloned allospecific Th cells to induce B cell proliferation and differentiation into antibody-forming cells is resistant to x-irradiation (21). We were therefore interested to determine the effect of x-irradiation on 86 helper activity for CTL generation. As presented in Table III T cell subset composition, T cell number, and cytolytic activity.
Two representative experiments, Table IV, demonstrate that 86 cells induce a reversal of the normal CD4 to CD8 ratio, such that after 6 d of culture > 50% of the recovered cells are CD8'. Moreover, after a week of expansion in the presence of IL-2, the proportion ofCD81 cells increases to > 80%. Perhaps most important, the CD8+ cells induced in the presence of clone 86 cells are readily expanded in vitro, to yield large numbers of highly efficient hapten altered self-reactive CTL (Fig. 6) .
Allospecific Th cells amplify altered self-cytolysis via lymphokine production. Two pieces of data suggest that clone 86 may secrete lymphokines that trigger CTL precursor differentiation and/or proliferation. First, as shown in Fig. 3 , very small numbers (0.1%) of clone 86 cells can markedly amplify altered self-CTL responses. Second, in our previous study (8) , we reported that 86 cells induced an allospecific CTL response against DR1-allogeneic stimulators providing a DR1+ stimulator was also present in culture. These "three-party" experiments were most consistent with the release oflymphokines by antigen (DRl)-activated clone 86 cells, which enhanced CTL activity ofprecursors that recognize MHC class I determinants on the DR1-stimulator.
To formally address the role of clone 86 derived lymphokines, 86 cells were cultured with final medium alone, DR1+, or DR1-x-irradiated, E-stimulators. Additional cultures contained 86 cells, DR1-stimulators and an antibody against a private idiotype of the T cell receptor expressed by clone 86. After 36 h, the supernatants were harvested, assayed for lymphokine content, and added to cultures containing responder T cells and hapten-altered autologous stimulators. As shown-in Table V , 86 cells, activated by antigen or antiidiotypic antibody, produce quantities of IL-4 that are maximally active in the CD23 induction bioassay, but levels of IL-2 that are barely detectable. In two separate experiments (Table VI) , supernatants derived from antigen-activated clone 86 cells effectively 
Discussion
The at least partial success of lymphokine-activated killer (LAK) cells in the treatment of advanced solid tumors (27) has served to focus attention on the potential ofadoptive immunotherapy for human disease. While the majority of LAK cells mediate NK-like activity, it has been recently demonstrated that high doses of IL-2 also induce tumor antigen specific, MHC class I-restricted CTL that are crucial for the elimination of macrometastases in several experimental models of tumor immunity (28, 29) .
With these issues in mind, we asked if cloned, alloantigen reactive human Th cells might be exploited in the development of more specific adoptive immunotherapy in man. As While NK cells are not induced by clone 86, we would emphasize that our data do not rule out activation of at least a subset of CD4' cells. In this regard, there is evidence in the murine system to suggest that IL-4 serves as an autocrine, The capacity of small numbers of clone 86 cells to trigger altered self-cytolysis suggested that these cells may function, at least in part, by the release of lymphokines. To address this point, 86 cells were activated with antigen (DRl+ stimulator cells) or antiidiotypic antibody, supernatants assayed for lymphokine content and the capacity to induce altered self-reactive CTL. Our data confirm that clone 86 cells elaborate soluble mediators which can support the generation of hapten altered self-reactive CTL. Of interest, the supernatants that were most efficient in CTL generation contained only trace amounts of IL-2, but substantial amounts of IL-4. These results suggest that clone 86 may represent a human equivalent of the murine TO2 subset, described by Mosman et al., which preferentially secretes IL-4 and IL-5, but little IL-2 or INFgamma (10) . Moreover, the possibility that clone 86 may amplify altered self-cytolysis, at least in part, by production of IL-4 is in agreement with a recent report by Widmer et al. documenting the capacity of recombinant (r) IL-4 to enhance allospecific CTL responses by human peripheral blood T cells without amplifying LAK cell activity (31) While the importance oflymphokines in CTL activation is clear, it should be emphasized that lymphokines may not represent true "hormones" of the immune system, acting at great distances from their site of production. Rather, these molecules are likely to function locally to amplify the response of antigen-activated lymphocytes in close proximity to the lymphokine-secreting cell (34) . For this reason, the positive effect of clone 86 derived lymphokines, readily detected in our in vitro model of altered self-cytolysis, is likely to be lost in the in vivo situation. These considerations, combined with the intriguing possibility of antigen binding and presentation by activated Th cells (18, 19) (7) .
